Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label Phase II Study of the Efficacy of Combination Bortezomib-containing Regimens in the Treatment of Newly Diagnosed Patients With t (4; 14) Positive Multiple Myeloma

NCT00570180 is registered in ClinicalTrials.gov with University Health Network, Toronto as lead sponsor.

NCT NCT00570180
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00570180 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label Phase II Study of the Efficacy of Combination Bortezomib-containing Regimens in the Treatment of Newly Diagnosed Patients With t (4; 14) Positive Multiple Myeloma
Lead sponsor
University Health Network, Toronto
Phase
Phase 2
Overall status
Completed
Start date
August 25, 2008
Completion date
September 15, 2015
Enrollment
36 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

multiple myeloma